http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3340873-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20a7f6607ad2493e6e7be777aa676821 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 |
| filingDate | 1983-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1985-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-3340873-A1 |
| titleOfInvention | USE OF MAGNESIUM SALICYLATE OR MAGNESIUM ACETYL SALICYLATE |
| abstract | The present invention relates to an area of use of the magnesium salts of salicylic acid and acetylsalicylic acid. Although present-day medicine is aware of the beneficial properties of these organic metal salts for prophylaxis and therapy when there is a risk of thrombosis and for rheumatic disorders, no one has thought of making use of their bivalent activity (antithrombotic and spasmolytic) in the therapeutic treatment and in the prevention of coronary heart disease. The invention remedies this by pointing out for the first time this bivalent activity and recommending magnesium salicylate and/or magnesium acetylsalicylate as coronary therapeutic agent. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3814856-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4335441-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0021507-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0021507-A3 |
| priorityDate | 1983-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.